Clinical Trials on Non-small-cell Lung Cancer (NSCLC) in United Kingdom

Total 4095 results

Massachusetts General Hospital
Genentech, Inc.

Unknown

Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

United States
University of Oxford
Cancer Research UK; Guy's and St Thomas' NHS Foundation Trust; NHS Lothian; National... and other collaborators

Completed

Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC (ARCADIAN)

Locally Advanced Non-Small Cell Lung Cancer

United Kingdom
Genzyme, a Sanofi Company

Completed

This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.

Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line

United States, Czech Republic, Hungary
GlaxoSmithKline

Completed

Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer

Lung Cancer, Non-Small Cell

United States, United Kingdom
Bayer

Recruiting

A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy Participants

Healthy Volunteers | Advanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 Mutation

United Kingdom
Clovis Oncology, Inc.

Terminated

A Dose Ascending Study of Gemcitabine Elaidate (CO-101) in Combination With Cisplatin

Lung Cancer | Solid Tumor | Non-small-cell Lung Cancer

United States, United Kingdom
howard safran
The Miriam Hospital; Rhode Island Hospital

Terminated

Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease

NSCLC | Lung Cancer | Metastatic Lung Cancer | Non-small Cell Lung Cancer

United States
AbbVie

Recruiting

A Study to Assess Prevalence of a Specific Protein Overexpression in Adult Participants With Non-Small Cell Lung Cancer (METRIX)

Non Small Cell Lung Cancer

Canada, United Kingdom
Eli Lilly and Company
Celgene

Completed

A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC

Carcinoma, Non-Small Cell Lung Cancer (NSCLC)

United States
Bristol-Myers Squibb

Completed

Treatment Patterns in Advanced Small Cell Lung Cancer (SCLC)

Lung Cancer

Spain, United Kingdom
University of California, San Francisco
AstraZeneca

Active, not recruiting

Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery

Stage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung Cancer

United States
Debiopharm International SA
Syneos Health

Terminated

A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung Cancer [NSCLC] (HALO)

Non-small Cell Lung Cancer

Spain, France, United Kingdom
Nasser Hanna
Genentech, Inc.

Terminated

Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer

NSCLC Stage IV | NSCLC, Recurrent

United States
Pfizer

Recruiting

Lorlatinib Continuation Study

NSCLC | Non-Small-Cell Lung Cancer

Spain, Taiwan, France, China, Singapore, Japan, United States
Concordia Laboratories Inc.

Completed

Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral Lung Cancer

Non-small Cell Lung Cancer (NSCLC) | Lung Metastasis

United States, Canada
Heather Wakelee
Eli Lilly and Company; Genentech, Inc.

Completed

Phase 2 Trial of Bevacizumab in Combination With Pemetrexed

Neoplasm Metastasis | Lung Cancer | Non-small Cell Lung Cancer (NSCLC)

United States
National Cancer Institute (NCI)

Terminated

Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical Resection

Stage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung Cancer

United States
Merck Sharp & Dohme LLC

Recruiting

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

Non-small Cell Lung Cancer (NSCLC)

Israel, Taiwan, United States, Australia, Hong Kong, Chile, Korea, Republic of, Canada, Malaysia
University College, London
Boehringer Ingelheim

Completed

Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity (DARWIN1)

Non-small Cell Lung Cancer

United Kingdom
Turning Point Therapeutics, Inc.

Terminated

A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC

Non-Small Cell Lung Cancer | NSCLC | Non Small Cell Lung Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | ALK Gene Mutation

United States, Australia, Korea, Republic of
Genmab

Terminated

Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer

Non Small Cell Lung Cancer

Belgium, United States, France, Netherlands, United Kingdom
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Terminated

A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer

NSCLC

United States
University of Leeds
University College London Hospitals; The Leeds Teaching Hospitals NHS Trust; University... and other collaborators

Recruiting

A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC (CONCORDE)

Non Small Cell Lung Cancer

United Kingdom
Biomea Fusion Inc.

Recruiting

Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

Colorectal Cancer | Pancreatic Cancer | NSCLC | Non Small Cell Lung Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | CRC | KRAS Mutation-Related Tumors | Relapsed Cancer | Refractory Cancer | Stage IV Non-small Cell Lung Cancer | Stage IV Colorectal Cancer | Stage III Non-small Cell Lung Cancer | Stage III NSCLC and other conditions

United States, Korea, Republic of
GlobeImmune
Memorial Sloan Kettering Cancer Center

Completed

A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation

NSCLC

United States
National Cancer Institute (NCI)

Terminated

A Phase II Study of Neo-Adjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2) Non-Squamous Cell Non-Small Cell Lung Cancer

NSCLC | Stage IIIA (N2)

United States, Croatia
Eikon Therapeutics

Recruiting

A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer

NSCLC

United States
Stanford University
AstraZeneca

Recruiting

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

Non-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage II

United States
Virginia Commonwealth University
National Cancer Institute (NCI)

Withdrawn

Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung Cancer

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung Cancer

United States
AstraZeneca

Completed

Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer

Advanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung Cancer

France, Korea, Republic of, United Kingdom, Spain
Syndax Pharmaceuticals

Completed

Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer (ENCORE110)

Breast Cancer | Lung Cancer | Non Small Cell Lung Cancer (NSCLC) | Estrogen Receptor Breast Cancer

United States
Ohio State University Comprehensive Cancer Center

Active, not recruiting

Hypofractionated Boost Before Chemoradiation for Patients With Stage II-III Non-small Cell Lung Cancer Unsuitable for Surgery

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung Cancer

United States
Astellas Pharma Inc
OSI Pharmaceuticals

Completed

Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients

NSCLC

United States
Eli Lilly and Company

Completed

A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

United States, United Kingdom
SystImmune Inc.

Recruiting

Study to Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Breast Cancer | Small Cell Lung Cancer | Nasopharyngeal Cancer | Esophageal Cancer | NSCLC | Lung Cancer | Non Small Cell Lung Cancer | SCLC | NPC

United States
Karen Kelly
Bristol-Myers Squibb; National Cancer Institute (NCI); Transgene

Completed

TG4010 and Nivolumab in Patients With Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer

United States
Kura Oncology, Inc.

Withdrawn

Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer

NSCLC

United States
National Cancer Institute (NCI)

Completed

FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
AstraZeneca

Completed

Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)

Advanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung Cancer

Belgium, United States, Korea, Republic of, Taiwan, United Kingdom, Netherlands
Eli Lilly and Company

Withdrawn

A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Metastatic Squamous Non-Small Cell Lung Cancer | Locally Advanced Squamous Non-Small Cell Lung Cancer

Italy, Romania, Germany, Belgium, Russian Federation, United States, United Kingdom
NanoMab Technology (UK) Limited
King's College London; Guy's and St Thomas' NHS Foundation Trust

Recruiting

PD-L1 Expression in Lung Cancer (PELICAN)

Non-Small Cell Lung Cancer

United Kingdom
AstraZeneca

Completed

A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ARCTIC)

Non - Small Cell Lung Cancer NSCLC

United States, France, Germany, Italy, United Kingdom, Belgium, Poland, Romania, Taiwan, Thailand, Canada, Korea, Republic of, Czechia, Hungary, Japan, Russian Federation, Hong Kong, Spain, Netherlands, Greece, Australia, Serbia, Bu... and more
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung Cancer

Tobacco Use Disorder | Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Limited Stage Small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB...

United States
University College, London
Cancer Research UK

Active, not recruiting

TRAcking Non-small Cell Lung Cancer Evolution Through Therapy (Rx) (TRACERx)

Non-small Cell Lung Cancer

United Kingdom
University College, London
Cancer Research UK

Unknown

Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer (SARON)

Non-small Cell Lung Cancer

United Kingdom
Incyte Corporation

Terminated

Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer

NSCLC (Non-small Cell Lung Carcinoma)

United States
Northwestern University
Bristol-Myers Squibb; National Cancer Institute (NCI)

Unknown

Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage III Non-Small Cell Lung Cancer

United States
Charu Aggarwal
Loxo Oncology, Inc.

Recruiting

Liquid Biopsy Based NGS in Newly Diagnosed NSCLC (iNUDGE)

Non Small Cell Lung Cancer Metastatic | Non-Squamous Non-Small Cell Neoplasm of Lung | Newly Diagnosed NSCLC

United States
Pfizer
Merck Sharp & Dohme LLC

Terminated

Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients

ALK-positive Advanced NSCLC

United States
Elevation Oncology
Merrimack Pharmaceuticals

Terminated

A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC (SHERLOC)

Adenocarcinoma | Non-Small Cell Lung Cancer | NSCLC | Heregulin

Spain, Canada, United States, Germany, Hungary, France

Clinical Trials on Non-small-cell Lung Cancer (NSCLC) in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations